摘要
目的 探讨氟伏沙明治疗抑郁症的临床疗效和安全性.方法 将80例抑郁症患者随机分为两组,每组40例,研究组口服氟伏沙明治疗,对照组口服阿米替林治疗,观察8周.于治疗前及治疗第1周、2周、4周、8周末采用汉密顿抑郁量表、汉密顿焦虑量表及副反应量表评定临床疗效和不良反应.结果 治疗后两组汉密顿抑郁量表、汉密顿焦虑量表评分均较治疗前显著下降（P＜0.01）,同期研究组均较对照组下降显著;治疗8周末,研究组显效率77.5%、有效率85.0%,对照组分别为75.0%、90.0%,两组差异均无显著性（χ2=0.069、0.457,P＞0.05）.研究组口干、便秘、头晕发生率,心电图异常率及治疗各时段副反应量表评分均显著低于对照组（P＜0.01）.结论 氟伏沙明治疗抑郁症疗效显著,与阿米替林相当,但氟伏沙明具有明显的抗焦虑作用,更适用于伴发焦虑症状的抑郁症,且起效快,安全性更高,依从性更好.
Objective To explore the efficacy and safety of fluvoxamine in the treatment of depression. Methods Eighty depression patients were randomly divided into two groups of 40 ones each, research group took orally fluvoxamine and control group did amitriptyline for 8 weeks. Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HA- MA） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 1st, 2nd, 4th and 8th week. Results After treatment, the HAMD and HAMA scores of both groups lowered more significantly compared with pretreatment （P^0.01）, so did those in the research than in the control group in the corresponging peroid; at the end of the 8th week, obvious effective and effective rates were 77.5% and 85.0% in the research and 75.0% and 90.00% in the control group, respectively, which showed no significant differences （x2 =0.069, 0. 457,P〉0. 05）. The incidences of dry mouth, constipation and dizziness, ECG abnormal rate and each peroid score of the TESS were all significantly lower in the research than in the control group （P〈0.01）. Conclusion Fluvoxamine has evident effect equivalent to amitriptyline in the treatment of depression, but has a notable antianxiety action, applies to depression with anxious symptoms, takes effect more rapidly, and has higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2011年第6期519-520,共2页
Journal of Clinical Psychosomatic Diseases
